Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
NCT05490511Phase 1Completed
- Sponsor
- Indiana University
- Start
- Oct 2022
- Primary completion
- Aug 2025
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cannabidiol (4 arms), sponsored by Indiana University. Primary endpoint: AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone at 27 days. Started Oct 2022; status: completed.
02
Drugs
cannabidiol
Beyond the preview
Go deeper on NCT05490511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490511.